* Study to Investigate the Absolute Bioavailability and ADME of [14C]AZD5363 (Capivasertib)(QSC205756)
Research type
Research Study
Full title
A Phase I Study to Investigate the Absolute Bioavailability, Absorption, Metabolism, Distribution and Excretion of [14C]AZD5363 (Capivasertib) in Healthy Male Subjects
IRAS ID
1005025
Contact name
Louise Perez
Contact email
Sponsor organisation
AstraZeneca AB
Eudract number
2022-000277-59
ISRCTN Number
ISRCTN15620353
Research summary
The Sponsor is developing the test medicine, Capivasertib, for the potential treatment of primary breast and prostate cancer. Cancer is a condition where cells in a specific part of the body grow and reproduce uncontrollably, causing a growth called a tumour. The cancerous cells can invade and destroy surrounding healthy tissue, including organs. The four most common types of cancer within the UK are: breast, lung, prostate and bowel cancer. This two-part healthy volunteer study will try to identify the absolute bioavailability (amount of the test medicine that enters the blood stream), mass balance recovery (how much radioactivity can be recovered from the urine and faeces) and the rates and routes of elimination of the test medicine. Two out of three recipes of the test medicine are radiolabelled with carbon-14. ‘Radiolabelled’ means that the test medicine has a radioactive component (carbon-14) which helps us to track where the test medicine is in the body.
This study will consist of two periods involving up to eight healthy male volunteers aged 30-65 and will take place at one non-NHS site.
In Part 1, volunteers will receive a single dose of 2 non-radiolabelled oral tablets in the fasted state followed by an intravenous infusion (solution into the vein) of radiolabelled test medicine 1 hour 15 mins minutes later. Volunteers will be discharged from the clinical unit on Day 5. In Part 2, volunteers will receive a single oral dose of a radiolabelled oral solution in the fasted state. Volunteers will be discharged on Day 8, however may be required to remain at the clinical unit until Day 10 if the mass balance criteria have not been met by Day 8. Volunteers will receive a follow up phone call between Day 15 and Day 19. Volunteer’s blood, urine and faeces will be taken throughout the study for analysis of the test medicine, radiation and for safety. Volunteers are expected to be involved in this study for approximately 9 weeks from screening to the follow-up call.REC name
East of England - Cambridge Central Research Ethics Committee
REC reference
22/EE/0180
Date of REC Opinion
10 Mar 2022
REC opinion
Further Information Favourable Opinion